205 related articles for article (PubMed ID: 26240484)
21. Usefulness of pT1 substaging in papillary urothelial bladder carcinoma.
Patriarca C; Hurle R; Moschini M; Freschi M; Colombo P; Colecchia M; Ferrari L; Guazzoni G; Conti A; Conti G; Lucianò R; Magnani T; Colombo R
Diagn Pathol; 2016 Jan; 11():6. PubMed ID: 26791567
[TBL] [Abstract][Full Text] [Related]
22. HMGB1 expression in urothelial carcinoma of the bladder.
Suren D; Yildirim HT; Atalay I; Sayiner A; Yildirim M; Alikanoglu AS; Sezer C
J BUON; 2018; 23(6):1882-1886. PubMed ID: 30610817
[TBL] [Abstract][Full Text] [Related]
23. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
[TBL] [Abstract][Full Text] [Related]
24. Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review.
Rouprêt M; Seisen T; Compérat E; Larré S; Mazerolles C; Gobet F; Fetissof F; Fromont G; Safsaf A; d'Arcier BF; Celhay O; Validire P; Rozet F; Irani J; Soulié M; Pfister C;
J Urol; 2013 Jun; 189(6):2069-76. PubMed ID: 23201497
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of heme oxygenase-1, S100 calcium-binding protein A4, and syndecan-1 expression in primary non-muscle-invasive bladder cancer.
Kim JH; Park J
Hum Pathol; 2014 Sep; 45(9):1830-8. PubMed ID: 24957789
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical comparison of MUC1, CA125, and Her2Neu in invasive micropapillary carcinoma of the urinary tract and typical invasive urothelial carcinoma with retraction artifact.
Sangoi AR; Higgins JP; Rouse RV; Schneider AG; McKenney JK
Mod Pathol; 2009 May; 22(5):660-7. PubMed ID: 19270645
[TBL] [Abstract][Full Text] [Related]
28. Comparative differences between T1a/b and T1e/m as substages in T1 urothelial carcinoma of the bladder.
Turan T; Efiloğlu Ö; Günaydin B; Özkanli Ş; Nikerel E; Atiş G; Çaşkurlu T; Yildirim A
Int Braz J Urol; 2018; 44(2):267-272. PubMed ID: 29219283
[TBL] [Abstract][Full Text] [Related]
29. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder.
Wild PJ; Herr A; Wissmann C; Stoehr R; Rosenthal A; Zaak D; Simon R; Knuechel R; Pilarsky C; Hartmann A
Clin Cancer Res; 2005 Jun; 11(12):4415-29. PubMed ID: 15958626
[TBL] [Abstract][Full Text] [Related]
30. Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.
Isharwal S; Huang H; Nanjangud G; Audenet F; Chen YB; Gopalan A; Fine SW; Tickoo SK; Lee BH; Iyer G; Chadalavada K; Rosenberg JE; Bajorin DF; Herr HW; Donat SM; Dalbagni G; Bochner BH; Solit DB; Reuter VE; Al-Ahmadie HA
Hum Pathol; 2018 Jul; 77():63-69. PubMed ID: 29601842
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of serum and urinary HER2/neu protein levels in primary non-muscle invasive bladder cancer.
Arikan O; Yýldýrým A; Ýsbilen B; Canakci C; Atýs G; Gurbuz C; Erol B; Ýsman FK; Ozkanli S; Caskurlu T
Int Braz J Urol; 2015; 41(6):1080-7. PubMed ID: 26742964
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemistry of cytokeratin (CK) 5/6, CD44 and CK20 as prognostic biomarkers of non-muscle-invasive papillary upper tract urothelial carcinoma.
Jung M; Kim B; Moon KC
Histopathology; 2019 Feb; 74(3):483-493. PubMed ID: 30286252
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
[TBL] [Abstract][Full Text] [Related]
34. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.
Zinnall U; Weyerer V; Compérat E; Camparo P; Gaisa NT; Knuechel-Clarke R; Perren A; Lugli A; Toma M; Baretton G; Kristiansen G; Wirtz RM; Cheng L; Wullich B; Stoehr R; Hartmann A; Bertz S
Hum Pathol; 2018 Oct; 80():55-64. PubMed ID: 29885409
[TBL] [Abstract][Full Text] [Related]
35. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications.
Krüger S; Weitsch G; Büttner H; Matthiensen A; Böhmer T; Marquardt T; Sayk F; Feller AC; Böhle A
Int J Cancer; 2002 Dec; 102(5):514-8. PubMed ID: 12432555
[TBL] [Abstract][Full Text] [Related]
36. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT
J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
[TBL] [Abstract][Full Text] [Related]
38. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.
Quintero A; Alvarez-Kindelan J; Luque RJ; Gonzalez-Campora R; Requena MJ; Montironi R; Lopez-Beltran A
J Clin Pathol; 2006 Jan; 59(1):83-8. PubMed ID: 16394286
[TBL] [Abstract][Full Text] [Related]
39. Human epidermal growth factor receptor 2 (
Agrawal V; Bharti N; Pandey R
Arab J Urol; 2020 Sep; 18(4):267-272. PubMed ID: 33312739
[TBL] [Abstract][Full Text] [Related]
40. HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder.
Latif Z; Watters AD; Dunn I; Grigor KM; Underwood MA; Bartlett JM
Br J Cancer; 2003 Oct; 89(7):1305-9. PubMed ID: 14520464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
